24.9 C
New York
Tuesday, June 6, 2023

Insights Into BioPlus Acquisition Corp. (BIOS) Exposure By Institutions

After Hours

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Recently, Yahoo Finance discussed the stock, revealing that Avertix, Maker of First and Only FDA-Approved Implantable Heart Attack Warning System, to Become Publicly Traded via Merger with BIOS Acquisition Corporation.

Unlock the Hottest Top 10 Penny Stocks Today! Discover Now

Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.

Gain Access to Top 10 Penny Stocks Now!.


Stocks Info

This NASDAQ-listed company operates within the Shell Companies industry segment, falling under the Financial sector. At the end of the last regular session, the stock closed at $10.51 and fluctuated between $10.51 as its day high and $10.51 as its day low. The current market capitalization of BioPlus Acquisition Corp. is $308.05M. A total of 0.51 million shares were traded on the day, compared to an average of 160.26K shares.

Insider trades can also provide insight into a stock’s future direction. During the recent three months, BIOS has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 0 BUYs and 0 SELLs from insiders. Insiders purchased 0 shares during that period but sold 0.

Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, BIOS has a high of $10.52 and a low of $9.89.

As of this writing, BIOS has an earnings estimate of -$0.09 per share for the current quarter. EPS was calculated based on a consensus of 3 estimates, with a high estimate of -$0.04 per share and a lower estimate of -$0.14. The company reported an EPS of -$0.28 in the last quarter, which was -250.00% lower than expectations of -$0.08.

Balance Sheet Annually/Quarterly

In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. BIOS’s latest balance sheet shows that the firm has $635.54k in Cash & Short Term Investments as of fiscal 2021. There were $5.00M in debt and $179.14k in liabilities at the time. Its Book Value Per Share was $7.61, while its Total Shareholder’s Equity was $221.00M.

Analysts Opinion

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BIOS is Buy with a score of 5.00.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles